COCS: COlchicine in Cardiac Surgery
Study Details
Study Description
Brief Summary
Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. Colchicine possesses both anti-inflammatory and sympatholytic properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine contain a class IIB recommendation, but the ESC guidelines do not recommend this drug. More researches are needed to focus on reducing of side effects by optimizing the colchicine regimen to reduce the incidence of gastrointestinal side effects. It is believed that further research is needed to investigate the efficacy and safety of colchicine in these conditions.
This research is aimed to study the effectiveness of short-term administration of the drug.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. Postoperative AF is considered as a multifactorial phenomenon. Its pathogenesis is characterized by inflammation, oxidative stress and autonomic dysfunction. Several predisposing factors lead to the development of POAF, including pre -, intra-and postoperative factors. The main of them are age, previous history of major cardiovascular risk factors and ischemic reperfusion injury during surgery. Treatment of POAF involves drugs to control the frequency of rhythm in hemodynamically stable patients and other treatment regimens usually used for the treatment of AF. Intraoperative administration of beta-blockers and some antiarrhythmic drugs is recommended by international clinical guidelines. In addition, previous treatment consisting of the use of colchicine, magnesium sulfate, statins and antioxidants have reduced the incidence of postoperative AF. However, the results of large-scale randomized trials have observed the development of undesirable adverse reactions.
Despite these recommendations, the question of the correct regimen for prevention of POAF remains controversial. Colchicine possesses both anti-inflammatory and sympatholytic properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine contain a class IIB recommendation, but the ESC guidelines do not recommend this drug.
Two studies sequentially COPPS-1 and COPPS-2 evaluated the effect of colchicine on the incidence of POAF after open heart surgery (COPPS-1) and the development of postcardiotomy syndrome (COPPS-2). In COPPS-1, patients (n=336) were treated with colchicine from the third day after surgery for a month and showed a significant decrease of POAF after heart surgery over the entire follow-up period. 360 patients were evaluated in the COPPS-2 study. The incidence of POAF between the colchicine and placebo groups was comparable, although colchicine significantly reduced postpericardiotomy syndrome. The main limitation of the COPSS-2 study was the high rate of cessation of intervention (20% of participants), which had a significant impact on the outcome of the trial.
Based on the latest meta-analysis of the colchicine effect on POAF after heart surgery, it was found that it still reduces POAF compared with control (HR = 0.69, 95% IM 0.57-0.84, p = 0.0002) and the duration of hospital stay was reduced by 1.2 days (95% IM -1.89 to -0.44, p = 0.002); however, the frequency of adverse gastrointestinal events increased significantly (HR = 2.52, 95% IM 1.62-3.93, p < 0.0001). Despite the high level of side effects, a significant reduction of POAF outweighs the balance in the favor of its use. However, more researches are needed to focus on reducing of side effects by optimizing the colchicine regimen to reduce the incidence of gastrointestinal side effects. It is believed that further research is needed to investigate the efficacy and safety of colchicine in these conditions.
This research is aimed to study the effectiveness of short-term administration of the drug.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Colchicine Colchicine 1 mg day (COLCHICINA LIRCA ® ACARPIA Farmaceutici S.r.l.) |
Drug: Colchicine Pill
Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.
Other Names:
|
| Placebo Comparator: Placebo Sugar pill |
Drug: Placebo
Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of participants with postoperative atrial fibrillation. [Monitoring is carried out immediately after surgery and will be continued until the end of the 7th postoperative day.]
POAF detected on continuous ECG monitoring.
Secondary Outcome Measures
- Number of participants with lethal and non-lethal events. [Participants will be followed for the duration of the postoperative period up to the day of initial discharge from the hospital, an expected average of 7 days.]
The main nosocomial lethal and non-lethal events (death, stroke, myocardial infarction, heart failure).
- Fluid in the pericardium. [Diagnostics will be carried out on the 3rd and 5th day after surgery.]
Fluid in the pericardium evaluated by echocardiography.
- Fluid in the pleura. [Diagnostics will be carried out on the 3rd and 5th day after surgery.]
Fluid in the pleura evaluated by echocardiography.
- Acute kidney damage (according to the dynamics of creatinine clearance). [Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.]
Dynamics of creatinine clearance.
- Inflammation in blood plasma. [Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.]
Dynamics of biomarker of inflammation in blood plasma (neutrophils).
- Liver damage [Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.]
Dynamics of biomarkers of liver damage (aspartate aminotransferase, alanine aminotransferase).
Eligibility Criteria
Criteria
Inclusion Criteria:
Adult patients awaiting elective cardiac surgery (CABG and/or AVR (aortic valve replacement), who are willing and able to give informed consent for participation in the study and who are in sinus rhythm and not taking any antiarrhythmic medication, except beta-adrenergic blocking agents, at the time before surgery.
Exclusion Criteria:
-
History of persistent or long-term atrial fibrillation/atrial flutter
-
Congenital heart disease, except the bicuspid AV
-
Frequent VE/SVE, AV block 2-3 degrees
-
Use of corticosteroids during the last month
-
Taking any antiarrhythmic drugs, except beta-blockers, within the last 1 month
-
Prior "open" heart surgery
-
Moderate to severe renal failure (creatinine clearance < 50 ml / min)
-
History of obstructive hepato-biliary disease or other serious hepatic disease
-
Significant mitral valve disease (moderate or severe mitral regurgitation-eg. > grade II and/or mitral stenosis & mitral annular calcification).
-
Patient participation in another clinical trial
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Federal Center for Cardiovascular Surgery (Astrakhan) | Astrakhan | Russian Federation | ||
| 2 | Bakulev National Medical Research Center for Cardiovascular Surgery | Moscow | Russian Federation |
Sponsors and Collaborators
- Bakulev Scientific Center of Cardiovascular Surgery
Investigators
- Principal Investigator: Vladimir Shvartz, Bakulev National Medical Research Center for Cardiovascular Surgery
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- #2.20122019